Can the Credit Suisse deal lend enough confidence to Fed in fighting inflation?
High inflation and high interest regime in the longer term would present more complex challenges, not just liquidity
Ami Organics: Europe plus one trend is taking hold
For the specialty chemicals business, Ami Organics is expanding on the clientele side and investing in process engineering
NOCIL: What should investors do as company struggles with inventory correction?
NOCIL is aiming to address the shortfall in capacities, after FY24. It is in the process of de-bottlenecking capacities of certain grades, which will help it to meet the demand for one to two years more.
Is it time to look at this quality chemical play?
There are a few positive developments, both at the macro and micro levels, which investors should take note of
Apollo Hospitals: A credible profitability road map for pharmacy is the ask
Margin improvement continued in the mature hospitals division, but Apollo 24/7’s operating cost weighed on EBITDA
Global Health: Faster ramp-up in new facilities adds to financial health
Strong ramp-up in its newer facilities reflect the growing demand for high-end institutional healthcare facilities
Lupin: Why you need to avoid despite improving US business
The improvement in both top line and margins are expected to be gradual
KIMS: Ramp-up of newly acquired entities to be key growth driver
KIMS presents a play on the structural demand trend for healthcare facilities
Aarti Industries: Does it strike the right chemistry for the long term?
Earnings to be driven by capex spending over the medium term
Navin Fluorine: Keep this quality chemical business on radar during downcycle
Long-term thesis is improving but trading at an expensive multiple
Zydus Lifesciences: Transdermal opportunity to unfold
The US and domestic formulation businesses help the pharma company to do well in Q3
Divi’s Labs: Growth trajectory sharply lower, wait for value to emerge
Gross margin contraction and operating deleverage have brought operating margins to levels not seen historically and pose concerns in the mind of investors regarding the near- to medium-term prospects
SRF: Agrochemical opportunity offsets weakness in other areas
The demand for agrochemicals remains strong as the company remains focused on active ingredients while engaging with global innovators
Budget 2023: The devil is in the detail
The fine print reveals the tax implications of some of the budget proposals
US Fed: Signs of disinflation, but labour market still tight
An improving global outlook means that the growth premium enjoyed by the Indian market will reduce
Sun Pharma: Specialty remains strong but at a price
The scale-up in clinical trials for specialty products and timeline for the launch of the generic version of Revlimid would be the key monitorable.
Laurus Labs: Is the worst over?
Material pick-up in earnings for Laurus Labs is contingent on the completion of capex projects
Apcotex: Is it time to chip in?
Apcotex faces increased competition in India from international peers, as freight costs have dipped significantly, leading to the disappearance of pricing advantage.
Cipla: Sharp improvement in margins not likely to sustain
While the respiratory portfolio remains a significant part of the US portfolio, the peptides portfolio is a key watch in the near to medium term.
Another great quarter for Dr Reddy’s, but is it sustainable?
EMs are expected to remain the chief driver of top-line growth, driven by chronic therapies and biosimilars
Syngene: Timeline for follow-through in Zoetis contract key catalyst to watch
Another growth lever to watch in manufacturing is that of the Mangalore API facility. Here the USFDA approval is expected in H2FY24.
Atul Industries: Global growth remains a key factor to watch
Macro headwinds in the export markets and a fair valuation keep us on the sidelines.
Atul: Next few quarters are hard
On a QoQ basis, in Q3 FY23, volumes for most of the chemical companies are anticipated to decline, except for the fluorochemicals and agrochemical companies
Is there an opportunity to invest in the chemical sector?
Valuations for the sector are, by and large, not expensive but not cheap either. In some cases, it is close to the long-term averages and should be evaluated case by case.
- Money Mojo | Five instruments to help you save Income Tax Watch more
- 'Stand By Our Colleagues, Treat Crew The Way You Want To Be Treated': Indigo Boss Pieter Elbers Watch more
- Xi Jinping meets Putin in Moscow: China-Russia show of strength amid ICC arrest warrant row Watch more
- Mad rush for DLF's luxury housing project Arbour | Aakash Ohri & Ashok Tyagi interview Watch more
- The 82-Year-Old Living It Up | Home By The River | The Tenant Watch more